Functional disorders of the biliary tract: modern diagnostic criteria and principles of pharmacotherapy

The review article presents current data on functional disorders of the biliary system, taking into account the latest recommendations of experts of the Rome Foundation (Rome Criteria IV, 2016) and the Russian Gastroenterological Association (specialized clinical recommendations, 2018). According to modern concepts, biliary dysfunction is a group of functional disorders of the biliary system caused by motor disorders and increased visceral sensitivity. According to the literature data, the prevalence of functional disorders of GB and OS is 10-15%, and violation of OS function is revealed in 30-40% of patients who underwent cholecystectomy (CE). The presence of biliary pain is an obligatory condition in the diagnosis of functional disorders of GB and OS. Bilirubin and serum transaminases (AST, ALT) levels may increase in biochemical blood analysis in patients with functional OS disorder of biliary type, and pancreatic amylase and lipase in case of functional OS disorder of pancreatic type. Ultrasound examination of abdominal organs is considered to be the priority among instrumental methods. This technique allows to exclude organic lesions of both the GB and visualized ducts, and adjacent organs (GSD, biliary tract, liver and pancreas neoplasms). Magnetic resonance cholangiopancreatography (MRCP) is used as a clarifying method, which allows to visualize the state of biliary ducts throughout. Ultrasonic cholecystography is used to assess the contractile activity of the GB. When duct dilation is detected and/or when liver/pancreatic enzyme levels are elevated in the absence of changes according to MRCP data, it is reasonable to perform an endoscopic ultrasound examination. According to the latest recommendations of the Russian Gastroenterological Association (2018), the foundation of pharmacotherapy for this group of diseases are antispasmodics and ursodeoxycholic acid (UDCA).

1. Andreyev D.N., Zaborovsky A.V., Trukhmanov A.S., Mayev I.V., Ivashkin V.T. Evaluation of the functional gastrointestinal diseases concept from standpoints of Rome IV (2016) diagnostic criteria (review). Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Сoloproctology. 2017;27(1):4–11. doi: 10.22416/1382-4376-2017-27-1-4-11.

2. Maev I.V., Dicheva D.T., Popova M.G., Andreev D.N., Maevskaya E.A. Biliary tract dyskinesia. Moscow; 2019. 29 p. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=37222234.

3. Yakovenko E.P., Agafonova N.A. Biliary dyskinesia. Moscow; 2019. (In Russ.)

4. Cafasso D.E., Smith R.R. Symptomatic cholelithiasis and functional disorders of the biliary tract. Surg Clin North Am. 2014;94(2):233–256. doi: 10.1016/j.suc.2013.12.001.

5. Ivashkin V.T., Mayev I.V., Shulpekova Y.O., Baranskaya Y.K., Okhlobystin A.V., Trukhmanov A.S. et al. Diagnostics and treatment of biliary dyskinesia: clinical guidelines of the Russian gastroenterological Association. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):63–80. (In Russ.) doi: 10.22416/1382-4376-2018-28-3-63-80.

6. Cotton P.B., Elta G.H., Carter C.R., Pasricha P.J., Corazziari E.S. Rome IV. Gallbladder and Sphincter of Oddi Disorders. Gastroenterology. 2016;150(6):1420–1429.e2. doi: 10.1053/j.gastro.2016.02.033.

7. Abdelhamid M.O., Thiels C.A., Bingener J. Is functional gallbladder disease truly increasing? Results from the Rochester Epidemiology Project. Am J Surg. 2018;216(5):932–934. doi: 10.1016/j.amjsurg.2018.04.001.

8. Polunina T.E. Biliary dysfunction. Rome consensus IV. Terapiya = Therapy. 2017;6(16). (In Russ.) Available at: http://cholestazu.net/upload/Polunina.pdf.

9. Behar J., Corazziari E., Guelrud M., Hogan W., Sherman S., Toouli J. Functional gallbladder and sphincter of oddi disorders. Gastroenterology. 2006;130(5):1498–1509. doi: 10.1053/j.gastro.2005.11.063.

10. Wilkins T., Agabin E., Varghese J., Talukder A. Gallbladder Dysfunction: Cholecystitis, Choledocholithiasis, Cholangitis, and Biliary Dyskinesia. Prim Care. 2017;44(4):575–597. doi: 10.1016/j.pop.2017.07.002.

11. Vassiliou M.C., Laycock W.S. Biliary dyskinesia. Surg Clin N Am. 2008;88(6):1253– 1272. doi: 10.1016/j.suc.2008.07.004.

12. Petersen B.T. An evidence-based review of sphincter of Oddi dysfunction: part I, presentations with “objective„ biliary findings (types I and II). Gastrointest Endosc. 2004;59(4):525–534. doi: 10.1016/s0016-5107(04)00012-4.

13. Maev I.V., Andreev D.N., Dicheva D.T., Bektemirova L.G. Jaundice syndrome in clinical practice. Мoscow: Prima print; 2017. 48 p. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=29878009.

14. Pereira S.P., Gillams A., Sgouros S.N., Webster G.J.M., Hatfield A.R.W. et al. Prospective comparison of secretin-stimulated magnetic resonance cholangiopancreatography with manometry in the diagnosis of sphincter of Oddi dysfunction types II and III. Gut. 2007;56(6)809–813. doi: 10.1136/gut.2006.099267.

15. Sostre S., Kalloo A.N., Spiegler E.J., Camargo E.E., Wagner H.N. Jr. A noninvasive test of sphincter of Oddi dysfunction in postcholecystectomy patients: the scintigraphic score. J Nucl Med. 1992;33(6):1216–1222. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1597742.

16. Craig A.G., Peter D., Saccone G.T., Zeising P., Wychelrley A., Toouli J. Scintigraphy versus manometry in patients with suspected biliary sphincter of Oddi dysfunction. Gut. 2003;52(3):352–357. doi: 10.1136/gut.52.3.352.

17. Feldman M., Friedman L.S., Brandt L.J. (eds.). Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia: Elsevier Inc.; 2015. Available at: https://www.pdfdrive.com/sleisenger-and-fordtrans-gastrointestinal-and-liver-disease-2-volume-set-pathophysiology-diagnosis-management-d175286385.html.

18. Maev I.V., Kucheravy Yu.A., Tsukanov V.V., Eremnia E.Yu., Andreev D.N., Abdulhakov S.R. et al. Effectiveness of Mebeverine in patients with postcholecystectomy gastrointestinal spasm: results of prospective observational program “Odyssey„. Terapevticheskiy arkhiv = Therapeutic Archive. 2018;90(8):40–47. (In Russ.) doi: 10.26442/terarkh201890840-47.

19. Okoro N., Patel A., Goldstein M., Narahari N., Cai Q. Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis. Gastrointest Endosc. 2008;68(1):69–74. doi: 10.1016/j.gie.2007.09.046.

20. Carotti S., Guarino M.P., Cicala M., Alloni R., Sergeto F., Rabitti C., Morini S. Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterol Motil. 2010;22(8):866–e232. doi: 10.1111/j.1365-2982.2010.01510.x.

21. Magouliotis D.E., Tasiopoulou V.S., Svokos A.A., Svokos K.A., Chatedaki C., Sioka E., Zacharoulis D. Ursodeoxycholic Acid in the Prevention of Gallstone Formation After Bariatric Surgery: an Updated Systematic Review and Meta-analysis. Obes Surg. 2017;27(11):3021–3030. doi: 10.1007/s11695-017-2924-y.

22. Ilchenko A.A. Justification of ursodeoxycholic acid application in biliary tract functional disorders. Ehksperimental’naya i klinicheskaya gastroehnterologiya = Experimental & Clinical Gastroenterology. 2011;(9):108– 112. (In Russ.) Available at: https://cyberleninka.ru/article/n/obosnovanie-primeneniya-ursodeoksiholevoy-kisloty-pri-funktsionalnyhnarusheniyah-biliarnogo-trakta/viewer.